Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 3, 2009, Pages 515-523

  Bergval, Indra L ^a   Schuitema, Anja R J ^a   Klatser, Paul R ^a   Anthony, Richard M ^a  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

Drug resistance; Mutation rate; Tuberculosis

Indexed keywords

ISONIAZID; KATG PROTEIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CELL DIVISION; CONTROLLED STUDY; DELETION MUTANT; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; POINT MUTATION; POLYMERASE CHAIN REACTION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; INHIBINS; ISONIAZID; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POINT MUTATION; RIFAMPIN; SELECTION (GENETICS); SEQUENCE DELETION;

EID: 69049098197     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp237     Document Type: Article

References (54)

1. World Health Organization. Anti-tuberculosis Drug Resistance in the World. Report No. 4. Geneva: WHO, 2008; WHO/HTM/TB/2008.394.
2. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli. Am Rev Tuberc 1954; 69: 471-2.
3. Zhang Y, Heym B, Allen B et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-3.
4. Altamirano M, Marostenmaki J, Wong A et al. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis 1994; 169: 1162-5.
5. Stoeckle MY, Guan L, Riegler N et al. Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. J Infect Dis 1993; 168: 1063-5.
6. Goto M, Oka S, Tachikawa N et al. KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates. Mol Cell Probes 1995; 9 433-9.
7. Rouse DA, DeVito JA, Li Z et al. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: Effects on catalase-peroxidase activities and isoniazid resistance. Mol Microbiol 1996; 22: 583-92.
8. Herrera-León L, Molina T, Saíz P et al. New multiplex PCR for rapid detection of isoniazid-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2005; 49: 144-7.
9. Van Rie A, Warren R, Mshanga I et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 2000; 39: 636-41.
10. Zhang M, Yue J, Yang YP et al. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2005; 43: 5477-82.
11. Dalla Costa ER, Ribeiro MO, Silva MS et al. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 2009; 9: 39.
12. Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: E61.
13. Hazbón MH, Brimacombe M, Bobadilla del Valle M et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-9.
14. Wengenack NL, Uhl JR, St Amand AL et al. Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid. J Infect Dis 1997; 176: 722-7.
15. Coll P, Aragón LM, Alcaide F et al. Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona. Microb Drug Resist 2005; 11 107-14.
16. Mo L, Zhang W, Wang J et al. Three-dimensional model and molecular mechanism of Mycobacterium tuberculosis catalase-peroxidase (KatG) and isoniazid-resistant KatG mutants. Microb Drug Resist 2004; 10: 269-79.
17. Saint-Joanis B, Souchon H, Wilming M et al. Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis. Biochem J 1999; 338: 753-60.
18. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955-60.
19. Li Z, Kelley C, Collins F et al. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 1998; 177: 1030-5.
20. Abe C, Kobayashi I, Mitarai S et al. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol 2008; 46: 2263-8.
21. Guo H, Seet Q, Denkin S et al. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006; 55: 1527-31.
22. Heym B, Alzari PM, Honoré N et al. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1994; 15: 235-45.
23. Ramaswamy SV, Reich R, Dou SJ et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47 1241-50.
24. Marttila HJ, Soini H, Huovinen P et al. katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Antimicrob Agents Chemother 1996; 40: 2187-9.
25. Van Soolingen D, de Haas PE, van Doorn HR et al. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000; 182: 1788-90.
26. van Doorn HR, de Haas PE, Kremer K et al. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: A decade of experience in The Netherlands. Clin Microbiol Infect 2006; 12 769-75.
27. Kelley CL, Rouse DA, Morris SL. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 2057-8.
28. Sherman DR, Mdluli K, Hickey MJ et al. AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. Biofactors 1999; 10: 211-7.
29. Dhandayuthapani S, Zhang Y, Mudd MH et al. Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. J Bacteriol 1996; 178: 3641-9.
30. Wilson TM, Collins DM. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996; 19: 1025-34.
31. Sherman DR, Mdluli K, Hickey MJ et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272: 1641-3.
32. Sreevatsan S, Pan X, Zhang Y et al. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997; 41: 600-6.
33. Bergval IL, Vijzelaar RN, Dalla Costa ER et al. Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis. J Clin Microbiol 2008; 46: 689-99.
34. Luria SE, Delbrück M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28: 491-511.
35. Anthony RM, Schuitema AR, Bergval IL et al. Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency. Ann Clin Microbiol Antimicrob 2005; 4 9.
36. Bergval IL, Klatser PR, Schuitema AR et al. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett 2007; 275 338-43.
37. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-4.
38. Manca C, Paul S, Barry CE III et al. Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. Infect Immun 1999; 67: 74-9.
39. Riska PF, Jacobs WR, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: S4-S10.
40. Zhang Y, Young D. Strain variation in the katG region of Mycobacterium tuberculosis. Mol Microbiol 1994; 14: 301-8.
41. Telenti A. Genetics of drug resistance in tuberculosis. Clin Chest Med 1997; 18: 55-64.
42. Sajduda A, Brzostek A, Poplawska M et al. Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J Clin Microbiol 2004; 42: 2425-31.
43. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
44. Slayden RA, Barry CE III. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 2000; 2: 659-69.
45. Mdluli K, Swanson J, Fischer E et al. Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium. Mol Microbiol 1998; 27: 1223-33.
46. Heym B, Stavropoulos E, Honoré N et al. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 1997; 65: 1395-401.
47. Bifani P, Mathema B, Kurepina N et al. The evolution of drug resistance in Mycobacterium tuberculosis: From a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. J Infect Dis 2008; 198: 90-4.
48. Jenkins C, Claxton AP, Shorten RJ et al. Rifampicin resistance in tuberculosis outbreak, London, England. Emerg Infect Dis 2005; 11: 931-4.
49. Lipin MY, Stepanshina VN, Shemyakin IG et al. Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin Microbiol Infect 2007; 13: 620-6.
50. Hillemann D, Kubica T, Rüsch-Gerdes S et al. Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob Agents Chemother 2005; 49: 1229-31.
51. Rinder H, Dobner P, Feldmann K et al. Disequilibria in the distribution of rpoB alleles in rifampicin-resistant M. tuberculosis isolates from Germany and Sierra Leone. Microb Drug Resist 1997; 3: 195-7.
52. O'Sullivan DM, McHugh TD, Gillespie SH. The effect of oxidative stress on the mutation rate of Mycobacterium tuberculosis with impaired catalase/peroxidase function. J Antimicrob Chemother 2008; 62 709-12.
53. Chakravorty S, Aladegbami B, Motiwala AS et al. Rifampin resistance, Beijing-W clade-single nucleotide polymorphism cluster group 2 phylogeny, and the Rv2629 191-C allele in Mycobacterium tuberculosis strains. J Clin Microbiol 2008; 46: 2555-60.
54. Manjunatha UH, Boshoff H, Dowd CS et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103 431-6.